Blue People has named Luis Arregoces as the company’s first chief artificial intelligence officer. Photo courtesy of Blue People

A Houston-based software company has named its first chief artificial intelligence officer.

Blue People has named Luis Arregoces as the company’s CAIO. With 20 years of experience, Arregoces has led AI projects for global Fortune 100 companies in various industries.

He has a Ph.D. in Economics from the University of New Mexico and is an adjunct professor in Statistics and Data Science at the University of Houston. He previously led the Applied Intelligence and Data Science at Accenture's Innovation Hub.

“We are beyond excited to have Luis on board,” Alfredo Arvide, chief innovation officer of Blue People, says in a news release. “His leadership and vision will allow Blue People to help clients and C-level executives develop AI roadmaps and solutions for real-time analytics, secure data sharing, and technology-agnostic ecosystems that will shape the future of innovation across all industries in Houston and throughout the region.”

Blue People has offices in Houston, Austin, Texas, and Monterrey, México. Blue People was named People’s Choice: Startup of the Year at the 2023 Houston Innovation Awards. The company also recently participated in CodeLaunch Houston, where its startup partner won the judges' pick in the competition.

“I am honored to join Blue People and be a part of this historic moment,” Arregoces says in a news release. ”Together, we have the opportunity to shape the future of AI in Houston and beyond. AI’s versatility and transformative potential make it indispensable across all industries to drive innovations, efficiency, and competitiveness.”

Let's talk about dark data — what it means and how to navigate it. Graphic by Miguel Tovar/University of Houston

Houston expert: Navigating dark data within research and innovation

houston voices

Is it necessary to share ALL your data? Is transparency a good thing or does it make researchers “vulnerable,” as author Nathan Schneider suggests in the Chronicle of Higher Education article, “Why Researchers Shouldn’t Share All Their Data.”

Dark Data Defined

Dark data is defined as the universe of information an organization collects, processes and stores – oftentimes for compliance reasons. Dark data never makes it to the official publication part of the project. According to the Gartner Glossary, “storing and securing data typically incurs more expense (and sometimes greater risk) than value.”

This topic is reminiscent of the file drawer effect, a phenomenon which reflects the influence of the results of a study on whether or not the study is published. Negative results can be just as important as hypotheses that are proven.

Publication bias and the need to only publish positive research that supports the PI’s hypothesis, it can be argued, is not good science. According to an article in the Indian Journal of Anaesthesia, authors Priscilla Joys Nagarajan, et al., wrote: “It is speculated that every significant result in the published world has 19 non-significant counterparts in file drawers.” That’s one definition of dark data.

Total Transparency

But what to do with all your excess information that did not make it to publication, most likely because of various constraints? Should everything, meaning every little tidbit, be readily available to the research community?

Schneider doesn’t think it should be. In his article, he writes that he hides some findings in a paper notebook or behind a password, and he keeps interviews and transcripts offline altogether to protect his sources.

Open-source

Open-source software communities tend to regard total transparency as inherently good. What are the advantages of total transparency? You may make connections between projects that you wouldn’t have otherwise. You can easily reproduce a peer’s experiment. You can even become more meticulous in your note-taking and experimental methods since you know it’s not private information. Similarly, journalists will recognize this thought pattern as the recent, popular call to engage in “open journalism.” Essentially, an author’s entire writing and editing process can be recorded, step by step.

TMI

This trend has led researchers to open-source programs like Jupyter and GitHub. Open-source programs detail every change that occurs along a project’s timeline. Is unorganized, excessive amounts of unpublishable data really what transparency means? Or does it confuse those looking for meaningful research that is meticulously curated?

The Big Idea

And what about the “vulnerability” claim? Sharing every edit and every new direction taken opens a scientist up to scoffers and harassment, even. Dark data in industry even involves publishing salaries, which can feel unfair to underrepresented, marginalized populations.

In Model View Culture, Ellen Marie Dash wrote: “Let’s give safety and consent the absolute highest priority, with openness and transparency prioritized explicitly below those. This means digging deep, properly articulating in detail what problems you are trying to solve with openness and transparency, and handling them individually or in smaller groups.”

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.